New Formulation of PAH Medication Is Now Available

Share this content:

Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, is now commercially available, according to the drug's maker, Actelion Pharmaceuticals US, Inc., of South San Francisco, Calif.

The product is indicated for the long-term treatment of primary pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with the scleroderma spectrum of disease in New York Heart Association Class III and Class IV patients who do not respond adequately to conventional therapy. Epoprostenol for Injection is stable at room temperature for up to 24 hours after it has been diluted and administered, the company said in a press release.

“Patients with late-stage PAH are extremely ill and have little energy, so a therapy that is convenient could make a big difference in their daily lives,” said Vallerie McLaughlin, MD, Professor and Director of the Pulmonary Hypertension Program at the University of Michigan in Ann Arbor.

You must be a registered member of Renal and Urology News to post a comment.